Rockwell Medical, Inc. — 2017 Form 10-K Summary
Business context and reporting period
Fiscal year ended December 31, 2017; the filing was signed March 15, 2018. Rockwell manufactures hemodialysis concentrates and ancillary products and develops renal drugs, including Triferic and Calcitriol. Concentrates and related products generated more than 95% of 2017 revenue; the company supplied approximately 25% of the U.S. dialysis-concentrate market.
Financial performance and liquidity
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $57.3 million | $53.3 million |
| Gross profit / margin | $3.7 million / 6.5% | $6.8 million / 12.7% |
| Operating loss | $25.9 million | $20.2 million |
| Net loss / loss per share | $25.9 million / $0.51 | $19.8 million / $0.39 |
| Cash used in operating activities | $21.1 million | $12.5 million |
| Cash and cash equivalents | $8.4 million | $17.2 million |
| Available-for-sale investments | $24.6 million | $40.8 million |
| Working capital | $39.7 million | $68.4 million |
| Long-term debt | None | None |
Cash plus investments totaled approximately $33.1 million at year-end. Current assets were $48.8 million and current liabilities $9.1 million. Capital expenditures were $1.7 million. The company reported no material off-balance-sheet arrangements. The annual filing reports a fourth-quarter 2017 gross loss of $1.2 million and net loss of $9.0 million on revenue of $14.8 million.
Material changes versus prior period
- Revenue increased 7.5%, reflecting growth in domestic and international concentrate sales. Drug revenue remained insignificant; $0.2 million of drug-license revenue was recognized.
- Gross margin fell to 6.5% from 12.7%. Drug gross loss was $3.6 million, including a $3.5 million Triferic inventory reserve/write-off; concentrate gross profit also declined following pricing concessions to Baxter and higher delivery costs.
- SG&A increased $2.2 million to $23.3 million, primarily due to legal and professional costs associated with litigation, the Baxter settlement and the 2017 shareholder contest. R&D rose to $6.3 million from $5.8 million.
- Operating cash use increased by $8.7 million. Cash and investments declined by $24.9 million combined, while total assets fell to $58.8 million from $83.2 million.
Outlook, risks and unusual items
- Management said existing capital resources were adequate for its 2018 strategy and expected to fund operations for at least the year ahead, while warning that additional financing could be needed if commercial cash generation is insufficient. It expected R&D spending to remain around the prior two years’ range and positive operating cash flow only when drug products achieve substantial sales.
- Triferic is FDA-approved for iron replacement and hemoglobin maintenance in adult hemodialysis patients, but CMS separate reimbursement remained pending. Management did not expect significant Triferic sales before separate reimbursement and could not predict the decision or timing.
- Calcitriol commercialization awaited FDA review of a manufacturing-related supplement. The company anticipated completion of the review in the second quarter of 2018, but noted timing was uncertain.
- Triferic inventory exposure is material, with finite shelf lives and possible further write-offs if reimbursement or commercial sales are delayed. The filing gives differing finished-goods figures: one discussion cites $5.0 million, while another cites $1.5 million, with a $3.5 million reserve; verify the detailed inventory disclosures.
- Customer concentration is high: DaVita represented 50% of 2017 sales; Baxter accounted for 27% of direct sales. Baxter’s distribution agreement runs through October 2024, subject to termination provisions and potential fee refunds. A June 2017 arbitration settlement involved no payment by either party and included pricing concessions.
- The company cited a continuing SEC inquiry into accounts receivable, inventory and Baxter-related disclosures; it said it had cooperated and could not predict the inquiry’s outcome. A 2017 proxy contest and subsequent governance agreements also involved significant costs and management attention.
- The Tax Cuts and Jobs Act reduced the company’s deferred tax asset, but a full valuation allowance left no net deferred tax asset recorded. Management reported effective internal control over financial reporting, and the auditor issued unqualified opinions on the financial statements and controls.
Important facts for investors to verify
- Current status and expected timing of CMS separate reimbursement for Triferic, and the commercial adoption assumptions underlying management’s cash outlook.
- Triferic inventory quantities, shelf-life schedule, reserve adequacy and the inconsistent finished-goods amounts disclosed in the filing.
- Cash burn, remaining liquidity and financing needs if Triferic or Calcitriol sales are delayed.
- Baxter agreement economics, minimum purchase requirements, termination/refund triggers and the effect of pricing concessions on margins.
- Progress and regulatory timing for Calcitriol and international licensing milestones, including whether anticipated partner payments or sales materialize.
- Status and potential consequences of the SEC inquiry, and the continuing impact of customer concentration and shareholder activism.